MAP2K7 and cervical carcinoma: Pretreatment with inhibitor of MEK/Erk, U0126, partially attenuated PGRN-stimulated mTOR phosphorylation in H8 cells (Figure 2F), which was also confirmed in cervical cancer HeLa cells (Supplementary Figure S2B).